Biogen’s Aduhelm is the first approved treatment for early stage Alzheimer’s patients that may be able to slow the disease. WSJ explains how the drug interacts with brain cells, and why some ...

Research announced today is the first of its kind to suggest that anti-amyloid drugs can delay or even stop the progression of symptoms in people with early-onset Alzheimer's.

Biogen is pulling the plug on the controversial drug Aduhelm, the first drug cleared by government health officials for treating Alzheimer's in nearly two decades. The pharmaceutical giant is ...

Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from ...

Related stories Aduhelm's weight on Medicare could spur more drug-price reform talks With several million Americans diagnosed with Alzheimer's, Aduhelm could break the Medicare system, experts said.

A case study is the Alzheimer’s disease treatment Aduhelm, which drug maker Biogen laid to rest on Wednesday. “When searching for new medicines, one breakthrough can be the foundation that ...

But while Aduhelm clearly removed Alzheimer’s ... there may be a third Alzheimer’s drug hitting the market as early as this year. It’s called donanemab, a drug from pharmaceutical giant ...

A Boston College Center for Retirement Research report looks at the financial implications for Medicare of Alzheimer's drug Aduhelm The recent controversy over Alzheimer’s treatment Aduhelm—criticized ...

This investigative series explores the science, money and politics behind the approval of the Alzheimer’s drug aducanumab. Read to learn more about this controversial drug and its implications ...